<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371199</url>
  </required_header>
  <id_info>
    <org_study_id>57353</org_study_id>
    <nct_id>NCT03371199</nct_id>
  </id_info>
  <brief_title>The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.</brief_title>
  <official_title>The Effect of Normalization of Sodium on Bone Markers in Patients With Epilepsy. A Randomized Single-blinded Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the association between normalization of serum sodium levels and bone
      markers in patients with epilepsy and chronic hyponatremia.

      The study is a randomized, single blinded, placebo controlled study where participants will
      be randomized to either treatment with salt tablets or placebo tablets through 4 months. At
      the beginning and end of the 4 months bone markers will be measured.

      The investigators null-hypothesis is that there will be no difference in bone markers before
      or after the intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTX1 change</measure>
    <time_frame>At baseline and after 4 months intervention</time_frame>
    <description>bone markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P1NP change</measure>
    <time_frame>At baseline and after 4 months intervention</time_frame>
    <description>Bone markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DXA scan change</measure>
    <time_frame>At baseline and after 4 months intervention</time_frame>
    <description>Density measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function change</measure>
    <time_frame>At baseline and after 4 months intervention</time_frame>
    <description>Epitrack test, scale from 9-49 (9 worst score - 49 best score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality change</measure>
    <time_frame>At baseline and after 4 months intervention</time_frame>
    <description>Quoli 31, scale from 0-100 (0 lowest life quality - 100 best life quality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily pains</measure>
    <time_frame>At baseline and after 4 months intervention</time_frame>
    <description>VAS from 0-10 (0 no pains - 10 maximum pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Metabolic Bone Disease</condition>
  <arm_group>
    <arm_group_label>Sodium arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>Sodium chloride tablets, 250 mg</description>
    <arm_group_label>Sodium arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Starch tablets</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>Strarch tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Epilepsy requiring treatment for at least 2 years

          -  Known hyponatremia (2 subsequent s-sodium values &lt; 136 mmol/l)

          -  Age 18-80 years

          -  Danish speaking

          -  Signed form of prior consent

        Exclusion Criteria:

          -  Pregnancy and breastfeeding

          -  Known osteoporosis. DXA scan &lt; -2.5 T-score. Z-score is used for patients 50 years or
             younger.

          -  Undergoing treatment for osteoporosis

          -  Undergoing treatment with salt tablets

          -  Known SIADH

          -  Severe concomitant disease such as cancer or ischemic heart disease

          -  Alcohol, drug or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noémi B Andersen, DMSc, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Senoir consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah S Diemar, MD</last_name>
    <phone>6124 2752</phone>
    <phone_ext>0045</phone_ext>
    <email>sarah.seberg.diemar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noémi B Andersen, DMSc, MD</last_name>
    <phone>3863 3029</phone>
    <phone_ext>0045</phone_ext>
    <email>noemi.becser.andersen.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah S Diemar, MD</last_name>
      <phone>6124 2752</phone>
      <phone_ext>0045</phone_ext>
      <email>sarah.seberg.diemar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Noémi B Andersen, DMSc, MD</last_name>
      <phone>3863 3029</phone>
      <phone_ext>0045</phone_ext>
      <email>noemi.becser.andersen.01@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Fedorenko M, Wagner ML, Wu BY. Survey of risk factors for osteoporosis and osteoprotective behaviors among patients with epilepsy. Epilepsy Behav. 2015 Apr;45:217-22. doi: 10.1016/j.yebeh.2015.01.021. Epub 2015 Mar 24.</citation>
    <PMID>25812937</PMID>
  </reference>
  <reference>
    <citation>Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015 Sep 2;351:h3783. doi: 10.1136/bmj.h3783. Review.</citation>
    <PMID>26333528</PMID>
  </reference>
  <reference>
    <citation>Darbà J, Kaskens L, Pérez-Álvarez N, Palacios S, Neyro JL, Rejas J. Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study. BMC Public Health. 2015 Apr 2;15:324. doi: 10.1186/s12889-015-1684-7.</citation>
    <PMID>25880810</PMID>
  </reference>
  <reference>
    <citation>Wu FJ, Sheu SY, Lin HC. Osteoporosis is associated with antiepileptic drugs: a population-based study. Epileptic Disord. 2014 Sep;16(3):333-42. doi: 10.1684/epd.2014.0673.</citation>
    <PMID>25166266</PMID>
  </reference>
  <reference>
    <citation>Asconapé JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002 Mar;22(1):27-39. Review.</citation>
    <PMID>12170391</PMID>
  </reference>
  <reference>
    <citation>Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA; IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011 Feb;22(2):391-420. doi: 10.1007/s00198-010-1501-1. Epub 2010 Dec 24. Review.</citation>
    <PMID>21184054</PMID>
  </reference>
  <reference>
    <citation>Sejling AS, Thorsteinsson AL, Pedersen-Bjergaard U, Eiken P. Recovery from SIADH-associated osteoporosis: a case report. J Clin Endocrinol Metab. 2014 Oct;99(10):3527-30. doi: 10.1210/jc.2014-1572. Epub 2014 Jun 27.</citation>
    <PMID>24971663</PMID>
  </reference>
  <reference>
    <citation>Sejling AS, Pedersen-Bjergaard U, Eiken P. Syndrome of inappropriate ADH secretion and severe osteoporosis. J Clin Endocrinol Metab. 2012 Dec;97(12):4306-10. doi: 10.1210/jc.2012-2031. Epub 2012 Oct 17.</citation>
    <PMID>23076350</PMID>
  </reference>
  <reference>
    <citation>Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA, Resnick HE. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010 Mar;25(3):554-63. doi: 10.1359/jbmr.090827.</citation>
    <PMID>19751154</PMID>
  </reference>
  <reference>
    <citation>Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem. 2011 Mar 25;286(12):10864-75. doi: 10.1074/jbc.M110.155002. Epub 2010 Dec 6.</citation>
    <PMID>21135109</PMID>
  </reference>
  <reference>
    <citation>Himmerkus N, Sievers B, Bleich M. Carbamazepine affects water and electrolyte homoeostasis in rat--similarities and differences to vasopressin antagonism. Nephrol Dial Transplant. 2012 Oct;27(10):3790-8. doi: 10.1093/ndt/gfs107. Epub 2012 May 4.</citation>
    <PMID>22561584</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Sarah Seberg Diemar</investigator_full_name>
    <investigator_title>Medical Doctor, ph.d. student, principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We have currently no plan to share individual patient data, but if relevant if relevant it could occur.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

